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Vascular endothelial growth factor (VEGF) promotes angiogenesis, and elevated levels are found in plaques of
psoriasis. Two VEGF polymorphisms, þ 405 and 460, are associated with early-onset psoriasis and are close to
the functional activator protein-1 site (þ 419) through which retinoids, an established systemic therapy for
psoriasis, can block production of VEGF. We report that peripheral blood mononuclear cells (PBMCs) and
epidermal keratinocytes (KC) from patients with psoriasis demonstrate differential, genotype-dependent,
regulation of VEGF. For PBMCs, VEGF genotype distinguishes two groups of patients with psoriasis – ‘‘high and
low VEGF producers’’ (Po0.001). In contrast, KC production of VEGF is not genotype dependent. However, the
effects of all-trans retinoic acid (RA) on cellular expression of VEGF are determined by both cell type and
genotype. RA inhibits KC production of VEGF in a genotype-dependent manner (Po0.005) whereas RA
stimulates PBMCs production irrespective of VEGF genotype (Po0.001). We also report that the 460 VEGF
polymorphism appears to have a clinical pharmacogenetic role in predicting response or non-response of
psoriasis to acitretin (P¼ 0.01). In future, determination of VEGF gene polymorphisms and thus individual
patient VEGF ‘‘signatures’’ may be used as a prognostic factor for psoriasis susceptibility/severity and as a means
for optimizing treatment response.
Journal of Investigative Dermatology (2006) 126, 453–459. doi:10.1038/sj.jid.5700096; published online 29 December 2005
INTRODUCTION
Psoriasis occurs in 1–2% of the population of Europe and the
USA (Fry, 1988) and is associated with inappropriate vascular
expansion within the superficial dermis, abnormal keratino-
cyte proliferation and differentiation, and inflammation
(Griffiths and Voorhees, 1996; Creamer et al., 1997; Griffiths
et al., 2004). Angiogenesis is a common pathogenic
component of several diseases including inflammatory
arthritis (Brenchley, 2000) and psoriasis (Detmar et al.,
1994). The role of vascular endothelial growth factor (VEGF)
as a primary angiogenic factor has been confirmed in
experimental models of angiogenesis (Kim et al., 1993) and
is now under investigation in clinical disease (Detmar, 1996;
Ferrara, 1999). VEGF is a key angiogenic factor in psoriasis
and is produced by both epidermal keratinocytes (KC)
(Barnhill et al., 1984; Malhotra et al., 1989; Detmar et al.,
1995; Thomas, 1996) and peripheral blood mononuclear
cells (PBMCs) (Watson et al., 2000).
In early-onset psoriasis (p40 years; Type 1) (Henseler and
Christophers, 1985), genetic predisposition is an important
facilitator of disease expression in conjunction with environ-
mental triggers such as infection and stress (Fry, 1988;
Griffiths and Voorhees, 1996). Several genetic loci for
psoriasis have been identified as a result of genome scanning.
The gene for VEGF, which is located at chromosome 6p.21
(Mattei et al., 1996; Vincenti et al., 1996), is highly
polymorphic (Brogan et al., 1999; Renner et al., 2000;
Watson et al., 2000). Two commonly occurring single
nucleotide polymorphisms (SNPs) at positions þ405 (Gene-
bank number rs2010963) and 460 (Genebank number
rs833061) from transcription start have been implicated
as candidate SNPs in diseases with a putative angiogenic
basis (Awata et al., 2002; Summers AM, Brenchley PEC,
Morgan L, Baker PN (2002) Association of VEGF þ405 GG
polymorphism with pre-eclampsia. J Soc Gynecol Investig 9
(Suppl 1):80A; abstract no 43; Summers et al., 2005) and a
significant correlation has been observed between VEGF
protein production and the þ405 polymorphism in health
and disease (Watson et al., 2000; Lambrechts et al., 2003).
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The amount of VEGF is significantly increased in plaques
of psoriasis compared with normal skin (Detmar et al., 1994)
and these levels appear to correlate with clinical severity of
psoriasis (Bhushan et al., 1999). VEGF is also increased in the
plasma of patients with erythrodermic psoriasis (Creamer and
Barker, 1995; Creamer et al., 1996; Creamer et al., 2002). In
a previous study, we demonstrated a significant association
between the VEGF þ 405 SNP and patients with severe
psoriasis of early onset and also showed that the amount of
VEGF is significantly increased in the plasma of patients with
Type 1, early-onset, chronic plaque psoriasis (Young et al.,
2004). We have previously documented significant linkage
disequilibrium between the 460 and þ405 SNPs in the
VEGF gene (Watson et al., 2000) and therefore it is possible
that the þ 405 and 460 VEGF SNPs may exert significant
functional control over VEGF expression in psoriasis. Both
these SNPs are close to the activator protein-1 sites at 490
to 484 and þ419 to þ425, the latter implicated in retinoid
blockade of VEGF production (Diaz et al., 2000). A third-
generation retinoid – acitretin – is an established systemic
therapy for severe psoriasis but individual patient benefit is
variable (Griffiths et al., 2000), implying a possible role for
pharmacogenetics in predicting response.
We postulated that patients with psoriasis may have
increased systemic expression of VEGF consequent upon
programming at the genomic level and that regulation of VEGF
protein expression may be related to disease severity. The aims
of this project were five-fold: (i) to investigate whether the
460 polymorphism is associated with early-onset chronic
plaque psoriasis; (ii) to investigate whether the þ 405 or 460
polymorphism is associated with VEGF protein production in
patients with early-onset chronic plaque psoriasis; (iii) to
investigate whether KC and PBMCs production of VEGF, in
psoriasis patients, are under the same polymorphic control;
(iv) to examine the effects of all-trans retinoic acid (RA) on
VEGF protein production by KC and PBMCs; and (v) to
investigate whether the response of patients with psoriasis to
acitretin therapy is associated with VEGF genotype.
RESULTS
The 460 VEGF TT genotype is associated with Type 1 chronic
plaque psoriasis
The frequency of the 460 VEGF polymorphism, a C-T
transition, was investigated in a UK cohort of Type 1 psoriasis
patients and compared with population-matched controls.
Three hundred and thirty-three patients with Type 1 chronic
plaque psoriasis of a range of clinical severities and 101
healthy, population-matched control subjects were recruited
to the study. Forty-one patients were then excluded from
further analysis on the basis of a diagnosis of inflammatory
arthropathy. The final patient group consisted of 292 patients,
170 (58%) males and 122 (42%) females; with median age 40
years (standard deviation 14.5 years; range 16–80 years);
median age of psoriasis onset 18 years (standard deviation 9.7
years; range 0–40 years). There was significantly increased
frequency of the 460 TT genotype (P¼0.03; Figure 1) when
all psoriasis patients (n¼292) were compared with healthy
controls (n¼101).
The study group included patients and controls investi-
gated in our previous study (Young et al., 2004). Further
subjects were recruited as part of our ongoing effort to fine
map the SNPs/haplotypes in this area of the VEGF gene. In
our previous study, we demonstrated a significant association
between the VEGF þ 405 SNP and patients with severe
psoriasis psoriasis area and severity index (PASI)X12 (Young
et al., 2004) but, in contrast to the above findings, we
observed no significant association between the VEGF 460
SNP and psoriasis (Young et al., 2004). We were unable to
determine whether the strength of the þ 405 association to
severe psoriasis was maintained in this study as PASI scores/
assessments were not available on all patients in our cohort.
Influence of genotype on keratinocyte expression of VEGF in
psoriasis
KC had comparable production of VEGF at baseline for
genotypes of each VEGF SNP (Table 1). However, after
incubation with lipopolysaccharide (LPS), KC from patients
with the 460 CC genotype or the þ405 GG demonstrated
significant VEGF production (Po0.003) compared with
baseline, whereas LPS had no measurable effect on VEGF
production by KC from patients with either the 460 TT or
the þ 405 CC VEGF genotype (Table 1). Thus, VEGF
genotype appeared to determine the effect of LPS on VEGF
production.
Influence of genotype on PBMCs expression of VEGF in
psoriasis
It was possible to stimulate VEGF production by PBMCs of
both VEGF SNPs with RA and LPS. When compared to
patients with the 460 CC and þ405 GG genotypes PBMCs
from patients with the 460 TT genotype or þ405 CC
genotype produced significantly increased amounts of VEGF
at baseline (Po0.001) and after incubation with RA
(P¼0.001); and LPS (P¼ 0.008; Table 1). In contrast to KC:
VEGF genotype identified two groups of patients with respect
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Figure 1. Early-onset, chronic plaque psoriasis demonstrates significant
genetic association with the 460 TT VEGF genotype. The most common
SNP in the promoter region of the VEGF gene is situated at position 460
from transcription start. In patients with Type 1 chronic plaque psoriasis
(n¼292) there is significantly increased frequency of the 460 TT genotype
when compared with population-matched, healthy, controls (n¼101).
*Po0.05.
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to PBMCs production of VEGF – ‘‘low VEGF producers’’ and
‘‘high VEGF producers’’; and it was possible to effect
upregulation of in vitro VEGF production by PBMCs
irrespective of genotype.
RA, genotype, and keratinocyte expression of VEGF in psoriasis
RA significantly inhibited production of VEGF by KC from
patients with either the 460 CC or the þ405 GG genotype
(Po0.005) but had no significant effect on KC from patients
of either 460 TT or þ 405 CC VEGF genotype (Table 1).
RA, genotype, and PBMCs expression of VEGF in psoriasis
RA stimulated PBMCs to produce VEGF irrespective of 460
or þ 405 VEGF genotype (Po0.001; Table 1). Therefore, RA
appears to exert an opposite effect on PBMCs (increased
VEGF production) as compared to KC (inhibition of VEGF
production) from the same subject.
VEGF genotype and clinical response to acitretin in chronic
plaque psoriasis
One hundred and twenty-four patients with Type 1, early-
onset, chronic plaque psoriasis who had been or were
currently being treated with acitretin (minimum treatment
duration 3 months) were recruited to the study. Patients who
had an indeterminate response to acitretin or who were
intolerant to treatment were excluded from participation in
the study. The final study group consisted of 106 patients of
whom 57 were defined as having responded to acitretin
treatment and 49 defined as having failed therapy. Patient
demographics for the ‘‘responded to treatment group’’ and
the ‘‘failed treatment group’’ are illustrated in Table 2.
When genotype frequencies at the 460 site were
examined (Figure 2), there was a significant (P¼0.04)
increase in frequency of the 460 TT genotype in patients
who were non-responsive to acitretin (n¼ 49) compared to
those who demonstrated a clear treatment response (n¼ 57).
Patients with the 460 TT genotype were almost twice as
likely to fail therapy as to respond. Conversely, there was a
Table 1. VEGF production by keratinocytes (KC) and
peripheral blood mononuclear cells (PBMC), from
patients with early-onset psoriasis
460 (n =14) +405 (n =14)
VEGF CC (n=5) TT (n=9) GG (n=7) CC (n=7)
KC (pg/ml/100 mg protein)
Baseline 11087105 17447386 15637251 11537382
RA 6967871 12807208 98171631 10037238
LPS 174471472 17347405 208872102 10427325
PBMCs (pg/ml)
Baseline 97793 2307314 1187113 2537424
RA 1987163 5847973 2577343 65671285
LPS 545734 13657275 646794 15527359
1The ability of all-trans retinoic acid (RA) to downregulate vascular
endothelial growth factor (VEGF) production by KC is dependent on VEGF
genotype – patients with the 460 CC or the +405 GG genotypes showed
significantly reduced production of VEGF as compared with baseline
(Po0.005).
2The ability of lipopolysaccharide (LPS) to increase VEGF production by
KC is dependent on VEGF genotype – patients with the 460 CC or the
+405 GG genotypes showed significantly increased VEGF production as
compared with baseline (Po0.003).
3High or low production of VEGF by PBMC is determined by genotype –
patients with the 460 CC or +405 GG genotypes were ‘‘low VEGF
producers’’ (Po0.001) and
4High or low production of VEGF by PBMCs is determined by genotype –
patients with 460 TT or the +405 CC genotypes were ‘‘high VEGF
producers’’ (Po0.001).
5RA increases VEGF production by PBMCs independent of VEGF
genotype (Po0.001). VEGF levels are expressed in pg/ml/100 mg protein
for KC and in pg/ml for PBMC. All data are expressed as mean7standard
error of the mean.
Table 2. Demographic details of the subjects in the
acitretin response study
Acitretin responders
(n=57)
Acitretin non-responders
(n=49)
Sex
Male 77% (n=44) 77.5% (n=38)
Female 23% (n=13) 22.5% (n=11)
Age (years)
Median 47.5714 41713.4
Range 18–77 18–73
Age at psoriasis onset (years)
Median 18710 19.679.3
Range 2–37 4–40
Data are expressed as median7standard deviation.
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Figure 2. The clinical response of psoriasis to treatment with acitretin can be
predicted by VEGF genotype. In patients with Type 1 chronic plaque psoriasis
who are treated with oral acitretin, VEGF genotype is predictive of therapy
outcome. The 460 SNP is the most commonly occurring SNP in the
promoter region of the VEGF gene. The 460 TT genotype was associated
with non-response to oral acitretin whereas the 460 TC genotype was
associated with clearance/significant response to treatment. There were no
significant differences in genotype frequencies at the þ 405 site when
comparing acitretin responders and non-responders. *Po0.05; **Po0.01.
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significant (P¼ 0.01) increased frequency of the 460 TC
genotype in patients who responded to therapy with acitretin
(w2 test) compared to those who failed. Patients with the
460 TC genotype were almost twice as likely to respond as
to fail acitretin therapy. There were no significant differences
in frequency of the 460 CC genotype between responders
and non-responders to acitretin. In addition, a similar analysis
of genotypes at the þ 405 site and patient response to
acitretin treatment demonstrated no significant differences in
any of the þ405 genotype frequencies when comparing
acitretin responders (n¼57) to non-responders (n¼49;
Figure 2).
DISCUSSION
Experimental findings suggest that VEGF is a key cytokine in
skin inflammation (Kunstfeld et al., 2004) and also in the
pathogenesis of psoriasis (Detmar et al., 1994; Kunstfeld
et al., 2004; Young et al., 2004). Epidermal KC have been
cited as the main source of VEGF for physiological and
pathological cutaneous angiogenesis (Malhotra et al., 1989).
However, as this study illustrates, high/low PBMCs produc-
tion of VEGF appears to be under genotypic control and may
provide a key source of VEGF in inflammatory skin disease.
Leukocyte traffic into the dermis in psoriasis is enhanced by
local VEGF production – VEGF itself promotes vascular
permeability and is chemoattractant for monocytes and
macrophages that express the VEGF receptor flt-1 (Barleon
et al., 1996). Thus, given a suitable environmental trigger, an
initial increase in KC production of VEGF followed by
enhanced cutaneous leukocyte migration could lead to a
genetically programmed amplification of VEGF expression
with increased VEGF production by PBMCs both within the
skin and the peripheral circulation.
Both low and high production of VEGF in patients with
chronic plaque psoriasis were based on assays with PBMCs
and this was not observed in work with KC cultures.
However, we did not explore baseline levels of VEGF in KC
from non-psoriatics with similar genotypes and it is possible
that regulation of VEGF protein production by KC may be
indirectly affected by other inflammatory factors. VEGF
production was significantly downregulated in KC from
patients with either the 460 C allele or the þ405 G allele
following incubation with RA – a genotype-dependent effect.
In contrast, RA upregulated VEGF production in PBMCs –
irrespective of VEGF genotype. The mechanism by which RA
exerts opposite effects on VEGF production in KC versus
PBMCs warrants further investigation.
It is apparent, with at least nine psoriasis susceptibility loci
so far described, that psoriasis is polygenic (Capon et al.,
2004) and there may be several genotypically different but
phenotypically similar forms of chronic plaque psoriasis.
These genetically distinct subsets may be characterized by
different triggers, disease severity, age of onset, and perhaps
responsiveness to treatment. Our data suggest that the 460
TT and the þ405 CC VEGF genotypes are associated not
only with ‘‘high VEGF production’’ by PBMCs but that they
are also associated with a genetic susceptibility to develop
Type 1 chronic plaque psoriasis and severe disease,
respectively. Clearly, the challenge and opportunity for the
treatment of psoriasis in individuals with the ‘‘high VEGF
producing’’ genotype is in the identification of treatment
strategies that restore/downgrade the proangiogenic pheno-
type to normal.
Psoriasis is currently incurable and is a skin disease with
variable clinical severity (Griffiths and Voorhees, 1996).
Patients with severe disease or those unresponsive to topical
therapy (approximately 20% of those affected) may either
require in-patient treatment, phototherapy/photochemother-
apy or systemic therapy with drugs such as methotrexate,
ciclosporin, and acitretin (Gawkrodger, 1997). Response of
severe psoriasis to acitretin therapy is notoriously variable
thereby indicating a possible role for pharmacogenetics in
predicting treatment response. A predictive pharmacogenetic
test for retinoid efficacy has been the subject of research on
SNPs in other genes that has proven negative (E Campalani
et al., unpublished data). Retinoids block production of VEGF
through a direct effect on the VEGF gene (Diaz et al., 2000).
The functional activator protein-1 site at position þ419 in
the 50 untranslated region of the gene (Diaz et al., 2000) lies
immediately proximate to the þ405 and another activator
protein-1 site at 490 to 484 lies close to the 460 loci of
the VEGF gene where we have established that there is tight
linkage disequilibrium.
In this study, we have shown that the VEGF 460
genotype appears to be predictive of treatment outcome with
acitretin. However, further study is needed to confirm these
data in larger cohorts of patients. Although further investiga-
tion is required, the cell culture studies give some insights
into a possible mechanism for this: (i) Patients with the 460
TT genotype are significantly more likely to fail acitretin
therapy. In patients with this genotype there appears to be a
genetic angiogenic drive – in the form of significantly
increased PBMCs production of VEGF. Administration of
RA results in a significant increase in VEGF production by
PBMCs, but has no effect on VEGF production by KC. This in
vitro observation appears to translate to a ‘‘genetically
determined’’ failure to respond to a systemic retinoid in vivo.
(ii) Patients with the 460 CC genotype have an indifferent
treatment response to acitretin therapy and have minimal
VEGF production by PBMCs and KC. The addition of RA to
cell culture results in increased VEGF production by PBMCs
but a decrease in KC production of VEGF. It may be that in
these individuals who are ‘‘low VEGF producers’’ ‘‘anti-
angiogenic’’ therapy is likely to be relatively inappropriate
and/or ineffective. Interestingly, in a previous study (Young
et al., 2004) we described significantly lower plasma levels of
flt-1 in patients with psoriasis of the 460 CC genotype as
compared to those with the TC or TT genotype at the 460
locus. (iii) The 460 TC genotype appears to be significantly
associated with treatment success with acitretin. These
patients are heterozygotes and theoretically may have some
background genetic drive for angiogenesis mediated princi-
pally through upregulated PBMCs production of VEGF.
Although addition of RA in vitro could increase PBMCs
production of VEGF (through the T allele), there may also be a
significant anti-VEGF effect on KC (through the C allele).
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A direct antiangiogenic effect in the skin could result in
treatment success with acitretin for these patients.
To our knowledge, this is the first study to investigate
differential cellular control of VEGF gene expression. In
conclusion, genetic polymorphisms in the VEGF gene appear
to determine production of VEGF for different cell types that
in turn may contribute to the pathogenesis of psoriasis. On
the basis of VEGF haplotype, some individuals may be
predisposed to expression of a particular psoriasis phenotype.
In the future, it is possible that determination of VEGF gene
polymorphisms and thus individual patient VEGF ‘‘signa-
tures’’ may be used as a prognostic factor for psoriasis
susceptibility and severity and as a means of optimizing
response to treatment with systemic retinoids.
MATERIALS AND METHODS
Patients
Having established VEGF genotype in a large cohort of patients with
early-onset psoriasis at both the þ 405 (Young et al., 2004) and
460 loci (data as above), 14 of these subjects were recruited to the
cell culture study. Subjects were selected on the basis of genotype at
the þ 405 and 460 VEGF loci, which resulted in a study group
where seven patients had the þ 405 CC genotype and seven, the
þ 405 GG genotype; whereas nine had the 460 TT genotype and
five, the 460 CC genotype. Two, 6 mm diameter skin biopsies were
taken for KC culture from the uninvolved skin (at least 5 cm away
from a plaque of psoriasis) of each patient. The patients had not
received systemic therapy for at least 4 weeks or topical therapy for
at least 2 weeks before skin biopsy. At the same visit, each subject
had a 20 ml venous blood sample collected into EDTA-coated blood
tubes for PBMCs culture experiments.
For the two genetics studies, suitable patients were recruited from
the Dermatology Centre, Hope Hospital, Manchester, UK and the
Institute of Dermatology, St Thomas’ Hospital, London, UK. Study 1:
for the VEGF SNP association study 333 patients with Type 1 chronic
plaque psoriasis who had a range of clinical severities of psoriasis
were recruited, in addition to 101 population-matched, healthy
control subjects. Patients with psoriatic or other inflammatory
arthropathy, or who were pregnant or breastfeeding were excluded
from the study. Study 2: for the acitretin response study psoriasis
clinic databases were used to pre-identify 124 patients with chronic
plaque psoriasis who had previously been or were currently being
treated with acitretin. A minimum duration of 3 months’ therapy
with acitretin was required for study eligibility. Patients’ responses to
acitretin therapy were objectively assessed from psoriasis clinic
records and direct patient questioning. The clinician assessing the
patient response to acitretin was blinded to details of the VEGF
genotype and production. On the basis of a documented change in
disease severity, which was also corroborated by the patient,
patients were categorized by acitretin response into one of four
groups: (i) definite response; (ii) indeterminate response; (iii) definite
failure of therapy; and (iv) intolerant of acitretin. Patients were
excluded from the study if they had an indeterminate response or
were intolerant of acitretin therapy; psoriatic arthropathy; or were
either pregnant or breastfeeding.
For both studies, venous blood was collected into EDTA-coated
blood tubes for DNA extraction from all patients participating in this
part of the study. Samples were stored at 801C until required. The
studies adhered to the Declaration of Helsinki Guidelines; were
approved by the respective local research ethics committees and
required all subjects to give written, informed consent.
DNA preparation
Genomic DNA was isolated from whole blood and red cell pellets
using Qiagen QIAamp DNA blood midi kit (Qiagen Ltd UK,
Crawley, West Sussex, UK) as previously described (Young et al.,
2004). Briefly, samples of whole blood or red cell pellets were mixed
with protease and incubated at 701C for 10 minutes. After further
mixing with absolute ethanol, the samples were loaded into QIAamp
Midi columns and centrifuge filtered, allowing DNA to remain
within the filter but permitting residual waste to pass through. After
two washing steps, the entrapped DNA was eluted from the filter
with distilled water. Quantification of DNA concentration and purity
was performed using a spectrophotometer (Cecil Series II, Cecil
Instruments, Cambridge, UK).
VEGF genotyping
Genotyping of the 460 and þ 405 VEGF SNPs (Genebank numbers
rs833061 and rs2010963) was performed using the SNP genotyping
assay (Applied Biosystems, Foster City, CA). A 10 ml rather than a
25 ml reaction volume was used but otherwise the assay was
performed according to the manufacturer’s instructions. The primers
and probes were designed using the assays-by-designTM service for
the 460 SNP (Applied Biosystems) and were available from the
assays-on-demandTMservice for the þ 405 SNP (Applied Biosystems).
Each PCR contained 15 ng genomic DNA, 5 ml TaqMan Universal
PCR Master Mix, No AmpErases UNG, 0.5 ml 20X SNP Genotyping
Mix, and 4.5 ml DNase-free water. PCR and genotyping analysis was
performed using 96-well plates on an ABI PRISMs 7000 Sequence
Detection System (Applied Biosystems). Thermal cycling conditions
consisted of an initial denaturation step at 951C for 10 minutes
followed by 40 cycles at 921C for 15 seconds (denature) and 601C for
1 minute (anneal/extension).
Allelic discrimination using the TaqMan assay is possible
because the fluorescence signal generated by PCR amplification is
indicative of which alleles are present within the sample. The
technique is advantageous over conventional techniques such as
PCR-restriction fragment length polymorphism in that it requires no
post-PCR manipulation or agarose gel electrophoresis.
Keratinocyte culture method
The epidermis was isolated from the skin biopsies by overnight
digestion with dispase (Sigma-Aldrich Ltd, Poole, Dorset, UK), and
the subsequent epidermal sheets treated with trypsin/EDTA (Sigma-
Aldrich Ltd) to yield a cell suspension which was centrifuge pelleted,
resuspended in KC (serum-free) culture medium and seeded in T25
flasks. The culture medium used was MCDB-153 (Sigma-Aldrich
Ltd,) serum-free medium, calcium concentration 70 mM, and was
supplemented with histidine (37 mg/ml), isoleucine (98 mg/ml),
methionine (13 mg/ml), phenylalanine (15 mg/ml), tryptophan (9mg/
ml), tyrosine (20 mg/ml), ethanolamine (6.1 ml/l), phosphoethanol-
amine (14 mg/ml), hydrocortisone (0.18 mg/ml), insulin (5 mg/ml),
transferrin (5 mg/ml), epidermal growth factor (10 ng/ml), penicillin
G (5 IU/ml), and streptomycin (5 mg/ml) as previously described
(Todd and Reynolds, 1998). KC were expanded by serial passage and
used for experiments between passages 1 and 2 (Sambrook and
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Pollack, 1974; Peehl and Ham, 1980). Experiments were set up in
six-well, flat-bottomed cell culture plates with cells at B60%
confluence.
Keratinocyte protein analysis
The colorimetric DC protein assay (Bio-Rad Laboratories Ltd, Hemel
Hempstead, Hertfordshire, UK) was used to determine protein
concentration following detergent solubilization of the plate-
adherent KC according to the manufacturer’s instructions.
PBMCs culture method
PBMCs were isolated from individual subjects by centrifugation over
a Lymphoprep (Life Technologies Ltd, Paisley, UK) gradient and cells
resuspended in RPMI 1640 medium (Sigma-Aldrich Company Ltd,
Poole, UK) supplemented with 10% fetal calf serum (Sigma-Aldrich),
1% penicillin–streptomycin solution (Sigma-Aldrich) and 1% gluta-
mine (Sigma-Aldrich). PBMCs were cultured at 1 106 cells/ml in
5% CO2 at 371C in a humidified incubator. Experiments were set up
in 96-well, round-bottomed, cell culture plates with 2 105 cells in
each well. The same batch of fetal calf serum was used in all
experiments.
Experimental conditions
All experiments were performed in triplicate and unstimulated cells
acted as matched controls. Dose responses were performed for each
of the reagents to elucidate optimum concentrations for experiments.
The cell cultures were incubated with 1 ng/ml LPS; and 1 mM RA
(Sigma-Aldrich Ltd.) for 48 h. Cell culture supernatants were
harvested and stored at 201C before VEGF assay.
Human VEGF ELISA – cell culture supernatants
Cell culture supernatant levels of VEGF protein were measured using
a Duoset ELISA (R & D Systems, Abingdon, Bucks, UK) according to
the manufacturer’s instructions. Briefly, 96-well plates were coated
with goat anti-human VEGF capture antibody and incubated
overnight at room temperature. After a standard washing step, the
plates were blocked with block buffer for at least 1 hour and then re-
washed. Cell culture supernatant samples and standards were added
(in reagent diluent) to the wells and incubated for 2 hours at room
temperature. After a further washing step, biotinylated goat anti-
human VEGF detection antibody was added to each well and
incubated for 2 hours at room temperature. After a washing step, a
working dilution of streptavidin–HRP (streptavidin conjugated to
horseradish-peroxidase) was added to each well and incubated for
20 minutes at room temperature. After a further washing step,
substrate solution was added to each well for 20 minutes, after which
a ‘‘stop’’ solution was added and the plate read on a ThermoMax
plate reader (Molecular Devices, Sunnyvale, CA) at 450 nm. All
samples and standards were assayed in duplicate and buffers were
made up under sterile conditions and prepared daily. VEGF
standards were used to ascertain interplate variability.
Levels of VEGF protein were expressed as pg/ml for PBMCs as
PBMCs were cultured at a fixed concentration of 1 106 cells/ml.
However, KC were used with cells atB60% confluence and in view
of the possibility of interplate variability in cell concentration, levels
of VEGF protein were expressed as pg/ml/100mg of total protein
for KC.
Statistical analysis
The w2 test was used to compare differences in the observed
genotype frequencies for the acitretin response study. The relation-
ship between cellular production of VEGF and genotype was
assessed with the paired and unpaired Student’s t-test as appropriate;
Po0.05 was considered statistically significant.
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